Krystal Biotech (NASDAQ:KRYS) Announces Earnings Results

Krystal Biotech (NASDAQ:KRYS) released its earnings results on Monday. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26, FiscalAI reports. The firm had revenue of $127.34 million for the quarter, compared to analysts’ expectations of $125.77 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $332.29 on Monday. Krystal Biotech has a twelve month low of $184.02 and a twelve month high of $382.54. The firm has a market capitalization of $9.84 billion, a P/E ratio of 41.64 and a beta of 0.50. The company has a fifty day moving average of $337.46 and a 200-day moving average of $308.68.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 13.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on KRYS shares. Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, October 23rd. Zacks Research lowered shares of Krystal Biotech from a “hold” rating to a “strong sell” rating in a report on Friday, October 23rd. The Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a research report on Thursday, September 24th. They set a “buy” rating and a $441.00 price objective for the company. Bank of America increased their price objective on shares of Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, September 21st. Finally, Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They issued an “outperform” rating and a $400.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Krystal Biotech presently has an average rating of “Moderate Buy” and a consensus target price of $377.20.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.